Table 1.
Baseline characteristics of patients who underwent positron emission tomography/computed tomography before dCRT for esophageal squamous cell carcinoma.
| Characteristics | Patients | % |
|---|---|---|
| Median age, years (IQR) | 56 (50–62) | |
| Male sex | 109 | 97.3 |
| ECOG | ||
| 0 | 20 | 17.9 |
| 1 | 89 | 79.5 |
| 2 | 3 | 2.7 |
| Tumor location | ||
| Upper | 52 | 46.4 |
| Middle | 50 | 44.6 |
| Lower | 10 | 8.9 |
| cT classification a | ||
| T1 | 2 | 1.8 |
| T2 | 10 | 8.9 |
| T3 | 48 | 42.9 |
| T4 | 52 | 46.4 |
| cN classification a | ||
| N1 | 19 | 17.0 |
| N2 | 55 | 49.1 |
| N3 | 38 | 33.9 |
| cStagea | ||
| IIB | 3 | 2.7 |
| IIIA | 13 | 11.6 |
| IIIB | 25 | 22.3 |
| IIIC | 71 | 63.4 |
| Median tumor length, cm (IQR) | 6.0 (4.9–8.0) | |
| Median SUVTumor (IQR) | 17.7 (14.2–23.9) | |
| Median SUVLN (IQR) | 9.9 (4.2–15.3) | |
| Median SUVLN/SUVTumor (IQR) | 0.59 (0.25–0.78) | |
| Chemotherapy | ||
| Carboplatin/Paclitaxel | 63 | 56.2 |
| Cisplatin/5-FU | 46 | 41.1 |
| Cisplatin/Paclitaxel | 3 | 2.7 |
| Median total RT dose, cGy (IQR) | 6000 (4500–6480) |
dCRT: Definitive chemoradiotherapy; ECOG: Eastern Cooperative Oncology Group performance score; 5-FU: 5-Fluorouracil; IQR: Interquartile range; LN: Lymph node; RT: Radiotherapy; SUV: Standardized uptake value. a Clinical staging according to Tumor-Node-Metastasis classification, 7th edition of the American Joint Committee on Cancer staging system.